Use of prokineticin-1 (PROK1), pregnancy-associated plasma protein A (PAPP-A) and PROK1/PAPP-A ratio to predict adverse pregnancy outcomes in the first trimester: a prospective study

Basit Öğe Kaydı
dc.authorwosidSAYIN, N. CENK/A-5801-2018
dc.contributor.authorInan, Cihan
dc.contributor.authorVarol, Fusun Gulizar
dc.contributor.authorErzincan, Selen Gursoy
dc.contributor.authorUzun, Isil
dc.contributor.authorSutcu, Havva
dc.contributor.authorSayin, N. Cenk
dc.date.accessioned2024-06-12T11:02:04Z
dc.date.available2024-06-12T11:02:04Z
dc.date.issued2018
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction: To compare the predictive effectiveness levels of prokineticin-1 (PROK1), pregnancy-associated plasma protein A (PAPP-A) and the PROK1/PAPP-A ratio in the first trimester for preeclampsia (PE), foetal growth restriction (FGR), gestational diabetes mellitus (GDM) and spontaneous preterm birth (SPB).Materials and methods: A total of randomly selected 162 pregnant women were included. Peripheral blood samples were obtained between 11(0/7) and 13(6/7) gestational weeks (GWs). All women were followed throughout the pregnancy and classified into five groups as having PE, FGR, GDM, SPB and uncomplicated pregnancies. The cut-off levels of the markers were identified to predict adverse outcomes.Results: PROK1 predicted PE with 83.3% sensitivity, 85.7% specificity at a value of >293.4pg/mL; at a value of >260.2pg/mL, PROK1 predicted FGR with 85.7% sensitivity, 72.5% specificity in the first trimester. The area under receiver operating characteristic (ROC) curve of PAPP-A was lower than that of PROK1 and PROK1/PAPP-A in differentiating PE and FGR from the uncomplicated group (p<.001). PROK1 levels and the PROK1/PAPP-A ratios in the SPB and GDM groups were lower than in the uncomplicated group (p<.01).Conclusions: Elevated PROK1 in the first trimester is a more effective marker than PAPP-A in the prediction of PE and FGR. Lower PROK1 levels are associated with the development of SPB and GDM.en_US
dc.description.sponsorshipTrakya University [2015/113]en_US
dc.description.sponsorshipThis study was supported by Research Fund of the Trakya University (project number: 2015/113).en_US
dc.identifier.doi10.1080/14767058.2017.1351536
dc.identifier.endpage2692en_US
dc.identifier.issn1476-7058
dc.identifier.issn1476-4954
dc.identifier.issue20en_US
dc.identifier.pmid28675948en_US
dc.identifier.scopus2-s2.0-85024397635en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2685en_US
dc.identifier.urihttps://doi.org/10.1080/14767058.2017.1351536
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21137
dc.identifier.volume31en_US
dc.identifier.wosWOS:000436337200006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal Of Maternal-Fetal & Neonatal Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFoetal Growth Retardationen_US
dc.subjectGestational Diabetes Mellitusen_US
dc.subjectPreeclampsiaen_US
dc.subjectPreterm Birthen_US
dc.subjectProkinecin 1en_US
dc.subjectIntrauterine Growth Restrictionen_US
dc.subjectEg-Vegfen_US
dc.subjectPreterm Deliveryen_US
dc.subject1st-Trimesteren_US
dc.subjectPreeclampsiaen_US
dc.subjectReceptorsen_US
dc.subjectCellsen_US
dc.subjectBirthen_US
dc.subjectRisken_US
dc.subjectTermen_US
dc.titleUse of prokineticin-1 (PROK1), pregnancy-associated plasma protein A (PAPP-A) and PROK1/PAPP-A ratio to predict adverse pregnancy outcomes in the first trimester: a prospective studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu